BioMarin Pharma (BMRN) Tops Q3 EPS by 15c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $65.68 +0.26%
EPS Growth %: +1,016.7%
Financial Fact:
Weighted average common shares outstanding, basic: 167.71M
Today's EPS Names:
ANAB, ANIX, MNY, More
EPS Growth %: +1,016.7%
Financial Fact:
Weighted average common shares outstanding, basic: 167.71M
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.07), $0.15 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $391.7 million versus the consensus estimate of $367.09 million.
GUIDANCE:
BioMarin Pharma sees FY2018 revenue of $1.47-1.53 billion, versus the consensus of $1.51 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
- Shoe Station Group Inc. (SHOE) Tops Q2 EPS by 11c ; Offers Guidance
- H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
